^
    Back
    Association details:
    Biomarker:HRD
    Cancer:Peritoneal Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Korea Biomedical Review
    Title:

    Lynparza adds indication for bevacizumab combo in ovarian cancer

    Published date:
    03/10/2021
    Excerpt:
    AstraZeneca’s Lynparza (ingredient: olaparib) obtained additional indication for combination therapy with bevacizumab in the first-line maintenance treatment of ovarian cancer in Korea....The Ministry of Food and Drug Safety granted the use of Lynparza in combination with bevacizumab as the maintenance therapy for adult patients with HRD-positive advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who responded to the first-line combo of platinum-based chemotherapy and bevacizumab.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    Therapeutic Goods Administration
    Excerpt:
    Lynparza in combination with bevacizumab is indicated for the...maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either...a deleterious or suspected deleterious BRCA mutation
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:...in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status...
    Test:
    BRACAnalysis CDx™, Myriad myChoice® CDx
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Lynparza in combination with bevacizumab is indicated for the:...maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability...
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NICE
    Title:

    Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer

    Published date:
    04/28/2021
    Excerpt:
    Olaparib plus bevacizumab is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults when...the cancer is associated with homologous recombination deficiency (HRD).
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    N Engl J Med
    Title:

    Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

    Excerpt:
    Eligible patients were 18 years of age or older and had newly diagnosed advanced (International Federation of Gynecology and Obstetrics [FIGO] stage III or IV), high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer....The duration of investigator-assessed progression-free survival was significantly longer in the olaparib group than in the placebo group (median, 22.1 months vs. 16.6 months; hazard ratio for disease progression or death, 0.59; 95% CI, 0.49 to 0.72; P<0.001)
    DOI:
    10.1056/nejmoa1911361
    Trial ID:
    PAOLA-1
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)

    Excerpt:
    ...Concordance in HRD status identification between VHIO-CARD-300 test and SOPHiA DDM™ Dx HRD Solution...
    Trial ID:
    STROBE